✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

GHK-Cu vs AHK-Cu: Broad Cosmetic Peptide vs Hair-Follicle-Selective Copper Peptide

These two molecules are structural cousins separated by a single N-terminal residue substitution — glycine in GHK, alanine in AHK. The change is small chemically but produces a meaningful shift in research-endpoint applicability. GHK-Cu is the broad-spectrum cosmetic-peptide reference compound; AHK-Cu is the hair-follicle-selective variant. This guide covers when to pick each and when to use both together.

Mechanism: same backbone, divergent activity

GHK is glycyl-L-histidyl-L-lysine, a naturally occurring tripeptide found in human plasma at concentrations that decline ~60% between age 20 and age 60. In its copper-chelated form (GHK-Cu, CAS 89030-95-5), the molecule has documented research effects on collagen synthesis (via TGF-β1 pathway upregulation), extracellular matrix remodelling (decorin and proteoglycan synthesis), hair-follicle stem-cell activation, and wound healing acceleration.

AHK is alanyl-L-histidyl-L-lysine — identical to GHK except for the N-terminal glycine replaced by alanine. The single residue change shifts the activity profile in the copper-chelated form (AHK-Cu) toward hair-follicle-selective effects. Published research shows AHK-Cu activates dermal-papilla cells (the follicle’s signalling hub) more efficiently than GHK-Cu at matched concentrations, with measurable hair-shaft thickening and anagen-phase prolongation in in-vitro follicle-culture models.

Both molecules require the Cu(II)-chelate form for the published activity at their cosmetic / dermatologic endpoints. The free peptide (without copper) is measurably active but at substantially smaller effect sizes — published comparisons typically show 5-10x amplification with copper chelation.

Comparison table

The hair-loss combination protocol

For hair-loss research specifically, the published combination protocol pairs GHK-Cu and AHK-Cu rather than treating them as competing options. The logic: GHK-Cu addresses multiple skin and scalp-tissue pathways at once (matrix remodelling, anti-inflammatory effects, partial follicle activity, vascular effects on follicle blood supply); AHK-Cu provides more concentrated activity at the dermal papilla specifically (the follicle signalling hub). Used together, the two cover the local follicle endpoint plus the broader scalp-tissue environment that supports follicle function.

This is distinct from the established small-molecule hair-loss treatments — finasteride works through 5α-reductase inhibition (suppressing DHT) and minoxidil works through potassium-channel-opener vasodilation. The copper peptides operate on a third mechanism family: direct dermal-papilla activation and matrix-environment effects on the follicle stem-cell niche. Combined research protocols use peptides as an additional mechanism arm alongside the established small-molecule treatments rather than as direct comparators. See: GHK-Cu for hair-loss research guide.

Which to pick (research-protocol logic)

• Pure collagen / anti-aging research: GHK-Cu standalone.
• Pure hair-follicle research: AHK-Cu standalone or combined with GHK-Cu.
• Wound-healing research: GHK-Cu, often combined with BPC-157 and/or TB-500.
• Broad cosmetic / anti-aging protocols: GHK-Cu — the more widely published mechanism.
• Hair-loss research alongside small-molecule comparators: AHK-Cu + GHK-Cu combined, plus the small-molecule arm separately for mechanism dissection.

FAQ

Why does the alanine-vs-glycine substitution change the activity profile so much?

The N-terminal residue affects the copper-chelate geometry and the surface charge profile of the molecule, which in turn affects how it docks against the relevant receptor / target proteins on dermal-papilla cells vs collagen-producing fibroblasts. The alanine substitution shifts the activity toward the follicle-specific endpoint while attenuating the broader-mechanism effects.

Is AHK-Cu just a less-effective GHK-Cu?

No — the molecules have different endpoint specificity. AHK-Cu is more effective than GHK-Cu at the dermal-papilla / hair-follicle endpoint specifically. GHK-Cu is more effective at the collagen / matrix / wound-healing endpoints. Pick by endpoint, not by relative potency.

Can both be applied topically?

Yes — both are stratum-corneum-permeable in published topical-formulation research at typical cosmetic-research concentrations. Topical formulations are the more common research route for both molecules. Subcutaneous administration is also published, primarily for the wound-healing arm of GHK-Cu research.

Do I need the copper chelate or can I use the free peptide?

The published effect-size literature predominantly references the Cu-chelate form. Free peptides have measurable activity but at substantially smaller effect sizes (typically 5-10x smaller in matched-concentration comparisons). The research-grade material on the MedsBase catalogue ships as the chelated form for both molecules.

What concentration is used in research?

Topical formulations typically use 0.005% – 0.05% (50 ppm to 500 ppm) for both molecules. Higher concentrations are used for specific endpoint research (matrix remodelling protocols at 0.1% concentration are published). Subcutaneous research dosing is typically 1-2 mg per dose for GHK-Cu.

How do they pair with BPC-157 in cosmetic research?

The pairing logic: GHK-Cu (or AHK-Cu) provides the local matrix / follicle mechanism; BPC-157 provides the systemic tissue-repair arm. In wound-healing research and post-procedural recovery protocols, the combination addresses both the local repair-substrate environment and the systemic repair-signalling arm. The GLOW Blend pre-bundles GHK-Cu with BPC-157 and TB-500 for this purpose.

Storage protocol?

Lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water or appropriate topical-formulation vehicle; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.

Bottom line

GHK-Cu and AHK-Cu are structural cousins with complementary research applicability. GHK-Cu is the broad cosmetic / anti-aging reference compound with extensive published research on collagen, matrix, wound healing, and partial follicle activity. AHK-Cu is the hair-follicle-selective variant with more concentrated activity at the dermal papilla. For hair-loss research, the two combine rather than compete — AHK-Cu provides the selective amplifier, GHK-Cu provides the broader scalp-tissue mechanism. See Best cosmetic peptides for full cluster context.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.